ClinicalTrials.gg
CompletedNCT06785012Moonlight-1Updated Sep 25, 2026

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

A Phase 2 interventional study of JNJ-89495120 and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 44 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Updated Sep 25, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.

Enrollment
36th of 52
105 · median 203
Started
2024
with 4 others
Phase 2
17 of 59
none open now
Registered
55th of 59
by date

Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 36th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2024, is one of 17 in phase 2, and was the 55th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Depressive Disorder, Major by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
  • Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
  • Were first diagnosed with depression before the age of 55
  • Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
  • Have taken 0, 1, or 2 treatments for depression in your current episode
  • (BMI) within the range 18 to 35 kilograms per square meter (kg/m\^2) at screening

Exclusion criteria

Exclusion Criteria:

  • Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
  • Current or past diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
  • Post-traumatic stress disorder within the past three years of screening
  • Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
  • History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
  • Known allergies, , or intolerance to JNJ-89495120 or its
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Arm 1: JNJ-89495120 Dose A

    Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study.

    Drug: JNJ-89495120

  • Experimental
    Arm 2: JNJ-89495120 Dose A and Dose B

    Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study.

    Drug: JNJ-89495120

  • Placebo comparator
    Arm 3: Placebo Group

    Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study.

    Drug: Placebo

Interventions

  • DrugJNJ-89495120

    JNJ-89495120 will be administered.

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5

    The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Time frame: Baseline up to Day 5

Secondary outcomes

  1. Change from Baseline in MADRS Total Score to Day 2

    The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Time frame: Baseline up to Day 2

  2. Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5

    The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity.

    Time frame: Baseline up to Day 2 and Day 5

  3. Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5

    The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology.

    Time frame: Baseline up to Day 5

  4. Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5

    The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21).

    Time frame: Baseline up to Day 5

  5. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

    Time frame: Up to approximately 18 weeks

  6. Number of Participants with Abnormalities in Vital Signs Parameters

    Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported.

    Time frame: Up to approximately 18 weeks

  7. Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities

    Participants with 12-lead ECG abnormalities will be reported.

    Time frame: Up to approximately 18 weeks

  8. Number of Participants With Abnormalities in Laboratory Parameters

    Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported.

    Time frame: Up to approximately 18 weeks

  9. Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)

    Participants with changes in weight/BMI will be reported.

    Time frame: Up to approximately 18 weeks

  10. Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

    Time frame: Up to approximately 18 weeks

  11. Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)

    The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials.

    Time frame: From Baseline up to 4 weeks

  12. Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)

    The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds.

    Time frame: From Baseline up to 4 weeks

  13. Plasma Concentrations of JNJ-89495120

    Plasma concentrations of JNJ-89495120 will be reported.

    Time frame: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

07

Study locations

44 sites
  • UAB Huntsville Regional Medical Campus
    Huntsville, Alabama 35801, United States
  • Chandler Clinical Trials
    Chandler, Arizona 85224, United States
  • IMA Clinical Research PC Phoenix
    Phoenix, Arizona 85012, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • CI Trials
    Bellflower, California 90706, United States
  • Wake Research PRI Encino
    Encino, California 91316, United States
  • National Institute Of Clinical Research
    Garden Grove, California 92844, United States
  • WR-Newport Beach
    Newport Beach, California 92660, United States
  • ATP Clinical Research
    Orange, California 92866, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Lumos Clinical Research Center LLC
    San Jose, California 95124, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Inland Psychiatric Medical Group Inc
    Temecula, California 92591, United States
  • Sunwise Clinical Research
    Walnut Creek, California 94596, United States
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
  • Gulfcoast Medical Research Center
    Fort Myers, Florida 33912, United States
  • The Medici Medical Research
    Hollywood, Florida 33021, United States
  • Advanced Research Institute of Miami
    Homestead, Florida 33030, United States
  • K2 Medical Research
    Maitland, Florida 32751, United States
  • Pharmax Research Clinic Inc
    Miami, Florida 33126, United States
  • Wellness Research Center
    Miami, Florida 33135, United States
  • Best Choice Medical and Research Service
    Pembroke Pines, Florida 33024, United States
  • Interventional Psychiatry of Tampa Bay
    Tampa, Florida 33629, United States
  • Health Synergy Clinical Research
    West Palm Beach, Florida 33407, United States
  • Synexus Clinical Research US Inc
    Atlanta, Georgia 30328, United States
  • iResearch Atlanta LLC
    Decatur, Georgia 30030, United States
  • Accelerated Clinical Research Group LLC
    Snellville, Georgia 30078, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Indiana University IU Health
    Indianapolis, Indiana 46202, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • Integrative Clinical Trials LLC
    Brooklyn, New York 11229, United States
  • Patient Priority Clinical Sites LLC
    Cincinnati, Ohio 45215, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • OSU Department of Psychiatry and Behavioral Health
    Columbus, Ohio 43210, United States
  • Paradigm Research Professionals, LLC
    Oklahoma City, Oklahoma 73116, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Revival Research Institute LLC
    McKinney, Texas 75071, United States
  • Alpine Research Organization
    Clinton, Utah 84015, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jun 2026, 17 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 17 months is close to that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 20, 2025
StartActual
Dec 26, 2024
Primary completionActual
Jun 25, 2026
CompletionActual
Aug 10, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
107→105
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Enrollment 107→105
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06785012
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Dec 26, 2024
Primary completion
Jun 25, 2026
Completion
Aug 10, 2026
Last update
Sep 25, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion